Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can allergy and glaucoma drugs regrow hair when delivered by microneedling?

NCT ID NCT07757867

Disease control Sponsor: Tanta University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This pilot study tests whether delivering cetirizine (an allergy medication) or latanoprost (a glaucoma drug) through microneedling can safely and effectively regrow hair in people with patchy alopecia areata. About 80 participants with recent-onset, limited patches of hair loss will be randomly assigned to one of four groups: microneedling plus cetirizine, microneedling plus latanoprost, microneedling plus triamcinolone acetonide (a standard steroid treatment), or microneedling alone. The main goal is to compare changes in scalp hair loss severity, measured by the SALT score, and to assess hair regrowth using clinical photographs.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Microneedling-assisted delivery of topical cetirizine 1% solution or latanoprost 0.01% solution, compared with microneedling plus triamcinolone acetonide (standard) and microneedling alone.
What this could lead to
If effective, this could offer a new, less invasive treatment option for patchy hair loss in alopecia areata, potentially improving hair regrowth without injections.
What could go wrong
This is a small pilot study, so results may not be conclusive or generalizable. The treatments may not outperform standard care, and side effects like skin irritation or unexpected reactions are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

80 people

The number who actually took part.

Started

Oct 2022

Finished

Oct 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Newly diagnosed cases of alopecia areata. * Patients of any age. * Both male and female patients. * Recent-onset patchy alopecia areata of ≤6 months' duration. * Presence of no more than two alopecia patches. * Stationary course of the disease. * Willingness to participate in the study. * Provision of written informed consent or parental/guardian consent for minors. Exclusion Criteria: * Extensive alopecia areata, including alopecia totalis or alopecia universalis. * Previous treatment of the alopecia areata lesions. * Active scalp infection. * Presence of associated dermatological, systemic, or autoimmune comorbidities. * Known allergy or hypersensitivity to any of the planned therapeutic agents.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alopecia areata are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alopecia areata

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alopecia areata Cetirizine Latanoprost Microneedling-assisted delivery

Contacts and locations

Locations

  • Tanta University

    Tanta, El-Gharbia Governorate, Egypt, 31527, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.